The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2017 | Myeloma 2017: an epigenetic research boom
The Myeloma 2017 meeting, held in Edinburgh, UK, saw more focus on epigenetic contributors to multiple myeloma (MM) than ever before, indicating a shift in the outlook and technological capabilites to research these factors in greater detail. In this interview, Felipe Prosper Cardoso, MD, of the University of Navarra, Pamplona, Spain, discusses the new studies highlighted at the meeting that were investigating the epigenetics of MM, including the CoMMpass study (NCT01454297), which is collecting the DNA methylation pattern profiles of its wide range of participants. Dr Prosper Cardoso highlights the benefits that a greater epigenetic understanding could have on the field of MM.
